Hematolojik Kanserlerde FISH Uygulamaları

FISH Analysis in Hematologic Cancers

Objectives: Fluorescence in situ hybridization (FISH) is a new technology which is helpful in the identification of chromosomal aberrations that are associated with hematologic malignancies or solid tumors. In this study, we evaluated the results of FISH analyses in patients with hematologic malignancies. Patients and Methods: FISH analyses were performed in bone marrow samples of 36 patients with an initial or confirmed diagnosis of hematologic malignancy. The cells were cultured for 4, 24, 48, or 72 hours depending on the type of disease. The images obtained from each case were processed on a computer with the SPOT RT program. Results: Using locus specific FISH probes, chromosomal translocation at t(9;22) was studied in 24 patients, t(15;17) was studied in 12 patients, t(8;21) and inv 16 t(16;16) were studied in six patients. In patients with an initial diagnosis of chronic myeloid leukemia, t(9;22) was positive in 60% to 90%. The detection of chromosomal aberrations associated with other hematologic malignancies ranged between 3% to 74%. The FISH analysis was also successful in showing decreases in chromosomal aberrations in patients under follow-up. Conclusion: FISH analysis is of particular help in both the initial diagnosis of, and monitoring chromosomal aberrations in the follow-up of hematologic malignancies. Turkish Başlık: Hematolojik Kanserlerde FISH Uygulamaları Anahtar Kelimeler: Kromozom aberrasyonu; hematolojik neoplaziler/ genetik; in situ hibridizasyon, floresans; lösemi, miyeloid/genetik; translokasyon, genetik Amaç: Son yıllarda geliştirilen FISH (fluorescence in situ hybridization) tekniği hem hematolojik hem de solid tümörlerle ilişkili olan kromozomal aberasyonların belirlenmesinde oldukça yararlı olmaktadır. Bu çalışmada hematolojik maligniteli olgularda yapılan FISH analiz sonuçları değerlendirildi. Hastalar ve Yöntemler: Hematolojik malignite öntanı sı konmuş veya izlemde olan 36 olgudan elde edilen kemik iliği örneklerinde FISH analizleri gerçekleştirildi. Hematolojik malignitelerin tipine göre 4, 24, 48, veya 72 saatlik hücre kültürleri yapıldı. Her bir olguya ait hücre görüntüleri SPOT RT programı yardımıyla bilgisayara aktarıldı. Bulgular: Otuz altı olgunun 24'ünde t(9;22), 12'sinde t(15;17), altısında t(8;21) ve inv 16 t(16;16) lokusa spesifik FISH probları kullanılarak araştırıldı. Kronik miyeloid lösemi öntanısı ile incelenen hastalarda t(9;22)'deki kromozomal translokasyon %60-90 oranında pozitif bulundu. Diğer hematolojik malignitelerde, ilişkili kromozomal aberasyonların varlığı %3-74 arasında değişen oranlarda gözlemlendi. Bu yöntemle takipteki hastalarda aberasyonlardaki düşüş başarıyla belirlenebildi. Sonuç: Özellikle hematolojik kanserlerde hem ön tanıda hem de izlemdeki olguların kromozomal aberasyonlarının belirlenmesinde FISH yöntemi oldukça önemli bir yardımcıdır.

___

  • Paietta E. Comments on the 2001 WHO proposal for the classification of haematopoietic neoplasms. Best Pract Res Clin Haematol 2003;16:547-59.
  • Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497-501.
  • Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 2003;138:819-30.
  • Bentley G, Palutke M, Mohamed AN. Variant t(14;18) in malignant lymphoma: a report of seven cases. Cancer Genet Cytogenet 2005;157:12-7.
  • Sawinska M, Ladon D. Mechanism, detection and clinical significance of the reciprocal translocation t(12;21)(p12;q22) in the children suffering from acute lymphoblastic leukaemia. Leuk Res 2004; 28:35-42.
  • Chang H, Wechalekar A, Li L, Reece D. Molecular cytogenetic abnormalities in patients with concur- rent chronic lymphocytic leukemia and multiple myeloma shown by interphase fluorescence in situ hybridization: evidence of distinct clonal origin. Cancer Genet Cytogenet 2004;148:44-8.
  • Fıratlı T. Akut lösemi etyopatogenezi: Demek sito- genetik önemli XXX. Ulusal Hematoloji Kongresi III. Hematoloji ilk Basamak Kursu. 10-14 Ekim 2003. İstanbul: Bilimsel Tıp Evi; 2003. s. 119-26.
  • Curry DJ, Smith TM. Measurement of SIL-TAL1 fusion gene transcripts associated with human T-cell lymphocytic leukemia by real-time reverse tran- scriptase-PCR. Leukemia Research 2003;27:575-82.
  • Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
  • Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller- Hermelink HK, Vardiman J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999;10:1419-32.
  • Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analy- sis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 1998;92:2322-33.
  • Siebert R, Weber-Matthiesen K. Fluorescence in situ hybridization as a diagnostic tool in malignant lym- phomas. Histochem Cell Biol 1997;108:391-402.
  • Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a sub- group of patients with an excellent prognosis. Leukemia 1995;9:1985-9.
  • Breit TM, Mol EJ, Wolvers-Tettero IL, Ludwig WD, van Wering ER, van Dongen JJ. Site-specific dele- tions involving the tal-1 and sil genes are restricted to cells of the T cell receptor alpha/beta lineage: T cell receptor delta gene deletion mechanism affects multiple genes. J Exp Med 1993;177:965-77.
  • McNeil N, Ried T. Novel molecular cytogenetic techniques for identifying complex chromosomal rearrangements: technology and applications in molecular medicine. Expert Rev Mol Med 2000; 2000:1-14.
  • Tanaka K, Arif M, Eguchi M, Shintani T, Kumaravel TS, Asaoku H, et al. Interphase fluorescence in situ hybridization overcomes pitfalls of G-banding anal- ysis with special reference to underestimation of chromosomal aberration rates. Cancer Genet Cytogenet 1999;115:32-8.
  • Lee DY, Cho HI, Kang YH, Yun SS, Park SY, Lee YS, et al. The role of fluorescence in situ hybridization (FISH) for monitoring hematologic malignancies with BCR/ABL or ETO/AML1 rearrangement: a comparative study with FISH and G-banding on 919 consecutive specimens of hematologic malignancies. Cancer Genet Cytogenet 2004;152:1-7.
  • Amare PS, Baisane C, Saikia T, Nair R, Gawade H, Advani S. Fluorescence in situ hybridization: a high- ly efficient technique of molecular diagnosis and predication for disease course in patients with myeloid leukemias. Cancer Genet Cytogenet 2001;131:125-34.